SGLT2 Inhibitor

Quick definition. SGLT2 inhibitors are a class of oral diabetes pills that lower blood sugar by making the kidneys excrete glucose in the urine. They are a different class from GLP-1 medications but are frequently compared with — and combined with — them.

How SGLT2 Inhibitors Work

SGLT2 stands for sodium-glucose cotransporter-2, a protein in the kidney that normally reabsorbs filtered glucose back into the blood. SGLT2 inhibitors block this transporter, so a portion of the body's glucose is excreted in the urine instead of being reclaimed. The result is lower blood sugar through a mechanism entirely independent of insulin. Because they also cause the kidneys to excrete sodium and water, these drugs modestly lower blood pressure and reduce fluid overload. Members of the class share the suffix "-gliflozin": empagliflozin (Jardiance), dapagliflozin (Farxiga), canagliflozin (Invokana), and ertugliflozin (Steglatro).

How They Differ From GLP-1 Medications

SGLT2 inhibitors and GLP-1 receptor agonists are separate drug classes that lower blood sugar in completely different ways and through different routes. SGLT2 inhibitors are once-daily oral pills that act on the kidney; most GLP-1 medications are injectables that act on the gut–brain–pancreas axis. On A1C reduction and weight loss, GLP-1 agonists — especially the newer high-dose agents — are generally more powerful. SGLT2 inhibitors typically produce modest weight loss (a few pounds) and A1C reductions of roughly 0.5% to 0.7%. Their standout strengths lie elsewhere, in organ protection.

Cardiovascular and Kidney Benefits

The defining feature of SGLT2 inhibitors is their proven benefit for the heart and kidneys, established in large cardiovascular outcomes trials. Studies such as EMPA-REG OUTCOME and DECLARE-TIMI 58 showed meaningful reductions in hospitalization for heart failure and slowing of kidney disease progression, and the class is now recommended for patients with heart failure or chronic kidney disease regardless of whether they have diabetes. GLP-1 agonists also have cardiovascular benefits, but the two classes shine in somewhat different domains — GLP-1s strongly for atherosclerotic events and weight, SGLT2 inhibitors strongly for heart failure and kidney protection.

Why They Are Often Discussed Together

Because their mechanisms are complementary and their organ-protective benefits only partly overlap, treatment guidelines increasingly recommend using an SGLT2 inhibitor and a GLP-1 agonist together in higher-risk patients with type 2 diabetes. They can be combined safely, and doing so addresses blood sugar, weight, cardiovascular risk, and kidney protection through different pathways at once. This is also why a patient researching GLP-1 options frequently encounters SGLT2 inhibitors in the same conversation.

Side Effects and Cautions

The most common side effects of SGLT2 inhibitors stem directly from spilling glucose into the urine: genital yeast infections and urinary tract infections occur more often. They can also cause dehydration and low blood pressure, particularly in older adults or those on diuretics. A rare but serious risk is diabetic ketoacidosis, which with this class can occur even when blood sugar is only mildly elevated ("euglycemic DKA"). These cautions are distinct from the gastrointestinal profile of GLP-1 medications, another reason clinicians weigh the two classes carefully for each patient.